Next Gen Diagnostics Developing Automated NGS Workflow for Outbreak Detection, Antibiotic Resistance Dx

NEWS STORY
Written By Casey-Drew Williams

Next Gen Diagnostics (NGD) is eyeing the clinical microbial genomics market with a highly automated, end-to-end next-generation sequencing and analysis workflow.

The Boston-based company is planning to deploy its technology into hospitals for NGS-based infectious disease control in early 2025, and is developing a sequencing-based diagnostic test to determine microbes' antibiotic susceptibility and resistance.

NGD Founder and CEO Paul Rhodes said the company was established in 2017 with the goal of achieving high-volume and low-cost whole-genome sequencing for routine clinical microbiology applications. Although the cost of sequencing has been going down in recent years, Rhodes said the company has been working to address two other major bottlenecks that hinder the wide adoption ofNGS in the field: sample preparation and bioinformatic analysis.

Casey-Drew Williams
Previous

Next Gen Diagnostics and Sheba Medical Center Announce Agreement for NGD to Sequence and Analyze Unique Collection of Highly Resistant Bacterial Infections
Next

Next Gen Diagnostics Announces New York State Department of Health’s Wadsworth Center Has Joined the NGD Cefiderocol Data Consortium for the Sequencing-Based Determination of Cefiderocol Resistance